Condition
Advanced Non Small Cell Lung Cancer (NSCLC)
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07574684Phase 2Not Yet RecruitingPrimary
Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC
NCT07259226Phase 2Recruiting
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
NCT01646125Phase 2TerminatedPrimary
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Showing all 3 trials